The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMyeloma 2023 | Using animal models & the microenvironment to better understand the biology of multiple myeloma
In this exclusive session chaired by María-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, Marta Chesi, PhD, Mayo Clinic, Phoenix, AZ, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, and José Ángel Martínez Climent, MD, PhD, University of Navarra, Pamplona, Spain, comment on future strategies and novel targets in multiple myeloma. The experts comment on recapitulating genomic heterogeneity in mice and compare genetic lesions and myelomagenesis in mice and humans. They then move on to using the microenvironment to predict measurable residual disease (MRD) outcomes prior to therapy, and finish by discussing risk models to identify smoldering myeloma. This session was filmed at the 16th International Workshop on Multiple Myeloma (iwMyeloma) held in Madrid, Spain.
